Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rockwell Medical Technologies (DE:RWMA)
FRANKFURT:RWMA
Rockwell Med (RWMA) Stock Price & Analysis
0 Followers
RWMA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.12 - €5.57
Previous Close€1.37
Volume0.00
Average Volume (3M)1.44K
Market Cap
€40.93M
Enterprise Value€43.89M
Total Cash (Recent Filing)$11.73M
Total Debt (Recent Filing)$14.88M
Price to Earnings (P/E)N/A
Beta1.30
Next Earnings
May 14, 2024EPS Estimate
-€0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,334,617
10 Day Avg. Volume0
30 Day Avg. Volume1,437
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.50
Price to Sales (P/S)0.56
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit10.77
Enterprise Value/Ebitda-10.20
Forecast
1Y Price Target
€6.56Price Target Upside379.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Rockwell Med News
PremiumCompany Announcements
Rockwell Medical Unveils Updated Corporate Insight Presentation
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
RWMA FAQ
What was Rockwell Medical Technologies’s price range in the past 12 months?
Rockwell Medical Technologies lowest stock price was €1.12 and its highest was €5.57 in the past 12 months.
What is Rockwell Medical Technologies’s market cap?
Currently, no data Available
When is Rockwell Medical Technologies’s upcoming earnings report date?
Rockwell Medical Technologies’s upcoming earnings report date is May 14, 2024 which is in 6 days.
How were Rockwell Medical Technologies’s earnings last quarter?
Rockwell Medical Technologies released its earnings results on Mar 21, 2024. The company reported -€0.047 earnings per share for the quarter, beating the consensus estimate of -€0.066 by €0.019.
Is Rockwell Medical Technologies overvalued?
According to Wall Street analysts Rockwell Medical Technologies’s price is currently Undervalued.
Does Rockwell Medical Technologies pay dividends?
Rockwell Medical Technologies does not currently pay dividends.
What is Rockwell Medical Technologies’s EPS estimate?
Rockwell Medical Technologies’s EPS estimate is -€0.04.
How many shares outstanding does Rockwell Medical Technologies have?
Currently, no data Available
What happened to Rockwell Medical Technologies’s price movement after its last earnings report?
Rockwell Medical Technologies reported an EPS of -€0.047 in its last earnings report, beating expectations of -€0.066. Following the earnings report the stock price went up 27.925%.
Which hedge fund is a major shareholder of Rockwell Medical Technologies?
Currently, no hedge funds are holding shares in DE:RWMA
---
Rockwell Med Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.56 (379.19% Upside)
€6.56 (379.19% Upside)
Blogger Sentiment
Bullish
DE:RWMA Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.50%
12-Months-Change
Fundamentals
Return on Equity
-47.68%
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Rockwell Medical Technologies
Rockwell Medical, Inc. engages in targeting end-stage renal disease and chronic kidney disease. Its dialysis products include hemodialysis concentrates, citrapure, dri-sate, safety data sheets,ancillary products, and renal pure. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.
---
RWMA Earnings Call
Q4 2024
0:00 / 0:00
---
RWMA Stock 12 Months Forecast
Average Price Target
€6.56
▲(379.19% Upside)
Technical Analysis
Rockwell Med
―
Aptose Biosciences
―
Citius Pharmaceuticals
―
Pulmatrix
―
Protagonist Therapeutics
―
Best Analysts Covering RWMA
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-16.95%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -16.95% per trade.
---